Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

Acta Diabetologica

Volumn 48, Issue 1, 2011, Pages 71-77

  Hsieh, Sheng Hwu ^a   Shih, Kuang Chung ^b   Chou, Chien Wen ^c   Chu, Chih Hsun ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Glucosidase inhibitors; Miglitol; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; MIGBOSE; MIGLITOL; PLACEBO; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CHINESE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

1-DEOXYNOJIRIMYCIN; AGED; BLOOD GLUCOSE; CHINA; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 79953321391     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-010-0220-6     Document Type: Article

References (31)

1. US Department of Health and Human Services, Centers for Disease Control and Prevention (2005) National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, GA, Centers for Disease Control and Prevention
2. HE Resnick GL Foster J Bardsley, et al. 2006 Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey Diabetes Care 29 531 537 16505501 10.2337/diacare.29.03.06.dc05-1254 (Pubitemid 44115349)
3. RS Lin WC Lee 1992 Trends in mortality from diabetes mellitus in Taiwan, 1960-1988 Diabetologia 35 973 979 1451956 10.1007/BF00401428 1:STN:280:DyaK3s%2Fotlygtw%3D%3D
4. CH Tseng 2004 Mortality and causes of death in a national sample of diabetic patients in Taiwan Diabetes Care 27 1605 1609 15220235 10.2337/diacare.27.7.1605 (Pubitemid 38857433)
5. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
6. SF Praet LJ van Loon 2009 Exercise therapy in type 2 diabetes Acta Diabetol 46 263 278 19479186 10.1007/s00592-009-0129-0
7. S Zanuso A Jimenez G Pugliese, et al. 2010 Exercise for the management of type 2 diabetes: a review of the evidence Acta Diabetol 47 15 22 19495557 10.1007/s00592-009-0126-3
8. SK Vijay M Mishra H Kumar, et al. 2009 Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes Acta Diabetol 46 27 33 18758684 10.1007/s00592-008-0054-7 1:CAS:528:DC%2BD1MXht1OrsrY%3D
9. SA Doggrell 2008 Clinical trials with thiazolidinediones in subjects with Type 2 diabetes-is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 9 405 420 18220491 10.1517/14656566.9.3.405 1:CAS:528: DC%2BD1cXhtFahsbY%3D (Pubitemid 351291785)
10. SS Lund L Tarnow M Frandsen, et al. 2009 Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial BMJ 339 b4324 19900993 10.1136/bmj.b4324
11. Pala L, Monami M, Lamanna C et al (2009) Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetol. Mar 17. [Epub ahead of print]
12. LK Campbell JR White RK Campbell 1996 Acarbose: its role in the treatment of diabetes mellitus Ann Pharmacother 30 1255 1262 8913408 1:CAS:528: DyaK28XntVCmtbY%3D (Pubitemid 26367448)
13. H Bischoff 1994 Pharmacology of alpha-glucosidase inhibition Eur J Clin Invest 24 Suppl 3 3 10 8001624 1:CAS:528:DyaK2cXmsVCksLc%3D
14. RR Holman J Steemson RC Turner 1991 Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia Diabetes Res 18 149 153 1842749 1:STN:280:DyaK3s7gsFGrsg%3D%3D
15. B Saunier RD Kilker Jr JS Tkacz, et al. 1982 Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases J Biol Chem 257 14155 14161 6216253 1:STN:280: DyaL3s%2Fls12nug%3D%3D (Pubitemid 13141298)
16. P Segal PU Feig G Schernthaner, et al. 1997 The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone Diabetes Care 20 687 691 9135927 10.2337/diacare.20.5. 687 1:STN:280:DyaK2s3otFKiuw%3D%3D (Pubitemid 27202513)
17. PS Johnston RF Coniff BJ Hoogwerf, et al. 1994 Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients Diabetes Care 17 20 29 8112185 10.2337/diacare.17.1.20 1:STN:280:DyaK2c7lsFOjuw%3D%3D
18. JL Chiasson L Naditch 2001 Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes Diabetes Care 24 989 994 11375358 10.2337/diacare.24.6.989 1:CAS:528:DC%2BD3MXks1agurw%3D (Pubitemid 33716364)
19. RF Coniff JA Shapiro D Robbins, et al. 1995 Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study Diabetes Care 18 817 824 7555508 10.2337/diacare.18.6.817 1:STN:280:DyaK28%2Fgt1Kqsw%3D%3D
20. RR Holman CA Cull RC Turner 1999 A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44) Diabetes Care 22 960 964 10372249 10.2337/diacare.22.6.960 1:STN:280:DyaK1MzgtVygtQ%3D%3D (Pubitemid 29241052)
21. American Diabetes Association 2006 Standards of medical care in diabetes-2006 Diabetes Care 29 1 S4 S42
22. Y Yamasaki N Katakami R Hayaishi-Okano, et al. 2005 alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness Diabetes Res Clin Pract 67 204 210 15713352 10.1016/j.diabres.2004.07.012 1:CAS:528:DC%2BD2MXhtlSmsrs%3D (Pubitemid 40254309)
23. RC Turner 1998 The UK prospective diabetes study. A review Diabetes Care 21 Suppl 3 C35 C38 9850487
24. FA van de Laar PL Lucassen RP Akkermans, et al. 2005 Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis Diabetes Care 28 154 163 15616251 10.2337/diacare.28. 1.154 (Pubitemid 40095800)
25. M Tominaga H Eguchi H Manaka, et al. 1999 Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study Diabetes Care 22 920 924 10372242 10.2337/diacare.22.6. 920 1:STN:280:DyaK1MzgtVygsg%3D%3D (Pubitemid 29241045)
26. JL Chiasson RG Josse R Gomis, et al. 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 59 2072 2077 10.1016/S0140-6736(02)08905-5 (Pubitemid 34680970)
27. DECODA Study Group; International Diabetes Epidemiology Group 2002 Cardiovascular risk profile assessment in glucose-intolerant Asian individuals-an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) Diabetes Med 19 549 557 10.1046/j.1464-5491.2002.00735.x (Pubitemid 35300675)
28. JA Balfour D McTavish 1993 Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus Drugs 46 1025 1054 7510610 10.2165/00003495-199346060-00007 1:STN:280:DyaK2c7nvVaitg%3D%3D (Pubitemid 24016644)
29. FL Diaz-Gutierrez JM Ladero M Diaz-Rubio 1998 Acarbose-induced acute hepatitis Am J Gastroenterol 93 481 9517669 10.1111/j.1572-0241.1998.481-1.x 1:STN:280:DyaK1c7ns1ynug%3D%3D
30. RJ Andrade M Lucena JL Vega, et al. 1998 Acarbose-associated hepatotoxicity Diabetes Care 21 2029 2030 9802764 10.2337/diacare.21.11.2029 1:STN:280:DyaK1M%2FhslOltg%3D%3D (Pubitemid 28478315)
31. Y Fujimoto M Ohhira N Miyokawa, et al. 1998 Acarbose-induced hepatic injury Lancet 351 340 9652620 10.1016/S0140-6736(05)78337-9 1:STN:280: DyaK1czhsVOhug%3D%3D (Pubitemid 28052706)